Stephens Investment Management Group LLC Has $41.72 Million Stock Position in ABIOMED, Inc. (NASDAQ:ABMD)

Share on StockTwits

Stephens Investment Management Group LLC grew its position in ABIOMED, Inc. (NASDAQ:ABMD) by 1.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 160,168 shares of the medical equipment provider’s stock after buying an additional 1,519 shares during the period. Stephens Investment Management Group LLC’s holdings in ABIOMED were worth $41,722,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the company. Amundi Pioneer Asset Management Inc. boosted its stake in ABIOMED by 314.3% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 648,206 shares of the medical equipment provider’s stock worth $185,120,000 after purchasing an additional 491,750 shares during the period. Kayne Anderson Rudnick Investment Management LLC boosted its stake in ABIOMED by 78.6% in the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 13,934 shares of the medical equipment provider’s stock worth $3,980,000 after purchasing an additional 6,134 shares during the period. Bessemer Group Inc. boosted its stake in ABIOMED by 132,163.4% in the 2nd quarter. Bessemer Group Inc. now owns 148,135 shares of the medical equipment provider’s stock worth $38,588,000 after purchasing an additional 148,023 shares during the period. Marshall Wace LLP boosted its stake in ABIOMED by 36.6% in the 1st quarter. Marshall Wace LLP now owns 4,549 shares of the medical equipment provider’s stock worth $1,299,000 after purchasing an additional 1,219 shares during the period. Finally, Country Trust Bank boosted its stake in ABIOMED by 11.1% in the 1st quarter. Country Trust Bank now owns 106,931 shares of the medical equipment provider’s stock worth $30,538,000 after purchasing an additional 10,667 shares during the period. 86.63% of the stock is owned by institutional investors.

In related news, COO David M. Weber sold 8,095 shares of the company’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $206.26, for a total value of $1,669,674.70. Following the transaction, the chief operating officer now owns 132,913 shares in the company, valued at approximately $27,414,635.38. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 3.40% of the stock is currently owned by corporate insiders.

A number of equities analysts recently weighed in on ABMD shares. BidaskClub raised shares of ABIOMED from a “strong sell” rating to a “sell” rating in a research note on Wednesday, July 24th. Morgan Stanley lowered shares of ABIOMED from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $325.00 to $215.00 in a research note on Thursday, August 1st. BTIG Research lowered shares of ABIOMED from a “buy” rating to a “neutral” rating in a research note on Thursday, August 1st. William Blair reissued a “buy” rating on shares of ABIOMED in a research report on Friday, August 2nd. Finally, SunTrust Banks reissued a “buy” rating and set a $340.00 price target on shares of ABIOMED in a research report on Friday, May 3rd. Three analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. ABIOMED has a consensus rating of “Hold” and a consensus target price of $316.50.

NASDAQ:ABMD traded up $2.10 on Thursday, hitting $192.23. 9,190 shares of the company’s stock were exchanged, compared to its average volume of 796,008. The business has a 50-day simple moving average of $244.53. The stock has a market capitalization of $8.70 billion, a P/E ratio of 53.24, a P/E/G ratio of 1.69 and a beta of 0.31. ABIOMED, Inc. has a 52 week low of $181.02 and a 52 week high of $459.75.

ABIOMED (NASDAQ:ABMD) last issued its earnings results on Thursday, August 1st. The medical equipment provider reported $1.00 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.01. The company had revenue of $207.70 million for the quarter, compared to analysts’ expectations of $210.96 million. ABIOMED had a net margin of 32.35% and a return on equity of 19.84%. ABIOMED’s quarterly revenue was up 15.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.95 EPS. On average, analysts predict that ABIOMED, Inc. will post 4.3 EPS for the current year.

About ABIOMED

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

See Also: Stock Symbols, CUSIP and Other Stock Identifiers

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.